Zacks Investment Research upgraded shares of Orion (OTCMKTS:ORINY) from a strong sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “
Shares of Orion stock opened at $15.10 on Tuesday. Orion has a 52-week low of $15.06 and a 52-week high of $21.17. The company has a market capitalization of $4,265.96, a PE ratio of 15.41, a PEG ratio of 19.26 and a beta of 0.43.
Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion and related companies with MarketBeat.com's FREE daily email newsletter.